Evolution of MSK’s Protocol Activation Core

Jocelyn Migliacci, MA, Marissa Kehoe, MS, Emily Valentino, MPH, Ann Rodavitch, MA

Memorial Sloan Kettering Cancer Center

Background
• Memorial Sloan Kettering Cancer Center (MSK) has a high volume of protocols in activation, opening an average of 36 prospective, retrospective and biospecimen protocols each month.
• Prior to 2018, protocol activation was managed locally by the Principal Investigators’ (PI) research teams without central oversight of study start-up.
• MSK identified that activation processes were inefficient and launched the Protocol Activation & Review and Human Research Protection Program (HRPP) centralizing activation and review committee management.

Goals
• Our initial centralized unit, which included oversight of protocol review committees and HRPP, allowed us to seamlessly coordinate protocol review and approval; however, the Protocol Activation Core (PAC) was only responsible for only a portion of all activation activities (shown in Figure 1).
• Due to the complexity of protocol activation, PAC was tasked with gradually streamlining and expanding the number of centralized activities, ensuring tasks were completed at the time of activation so that we can enroll patients to new treatments quickly.

Methods
• PAC was tasked with facilitating communication between the PI, local study team, and all other key stakeholders in activation, including the sponsor, finance, legal, etc., ensuring that all start up. requirements were fulfilled before opening a study to enroll patients.
• Over ~5 years, PAC gradually centralized most activation activities (Figure 1) which resulted in our team’s expansion (Figure 2).
• We have extensively evaluated the processes of tasks and focused significant effort to streamline processes, including identification of improvements and system enhancements to reduce task completion time and ensure these tasks were not delaying activation.

Outcome
• Forty-seven prospective studies have started activation in the expansion pilot, of which 17 studies have been activated to enroll participants.
• When comparing activated pilot studies to activated non-pilot studies (N=278) that started activation in the same timeframe, we have seen an improvement at all stages of activation (Figure 3).
• The most notable change was in the stage between IRB approval and open to enrollment (waiting to open) with a 44% decrease in median days.

Lessons Learn and Future
• We plan to gradually add research departments to the pilot throughout 2023 preparing for a full roll out in 2024.
• The pilot has allowed us to assess the size of the PAC team to ensure we’re “right-sized” to expand the pilot across all research departments.
• We have been and will continue to identify improvements to streamline workflows and evaluate activation metrics to ensure that we’re continuing to reduce the time it takes to activate studies.

Figure 1. Expansion of Protocol Activation Responsibilities over ~5 years

Centralization of study start up team with limited scope: centralizing some activation activities

<table>
<thead>
<tr>
<th>Year</th>
<th>Responsibilities</th>
</tr>
</thead>
</table>
| 2018 | Liaise all teams involved with activation  
|      | Create: Protocol order set (POS)  
|      | Initiate: data and material agreements  
|      | Draft and negotiate Informed Consent Form (ICF) travel forms and pill diaries, as applicable  
| 2020 | Gradual expansion of centralizing activation activities, such as protocol tools  
|      | Collect required protocol/sponsor specific forms from the sponsor and provide to study team for completion  
|      | Schedule and attend site initiation visit (SIK)  
|      | Alignment of Sr. Managers to provide a ‘concierge’ experience for all PIs  
| 2022-2023 | Continued expansion of most activation tools as an expansion pilot  
|      | Initiate: Correlative processing order set creation  
|      | Agreements (vendor, quality, purchase)  
|      | IRB set up  
|      | Radiation safety review  
|      | Research database (CRDB) set up  
|      | Solicit and coordinate with SAs, drug, and devices  
|      | Regulatory document collection and submission to sponsor  
|      | Study planning, facilitating and documenting  

Figure 2. Staffing Expansion over ~5 years

- Team in 2018 (N=12)
- Expanded in 2020 (24 new positions)
- Expanded in 2022 (17 new positions)

Figure 3. Graphical Depiction of Changes in Medians*

- Decrease in median days at every stage